Ladenburg, Germany, 25 May 2023 - Heidelberg Pharma AG (FSE: HPHA) announced that the company's shareholders approved the following proposed resolutions of the management with a large majority (between 96,30 % and 99,99 %) at today's ordinary virtual Annual General Meeting:
- Discharge of the members of the Management Board and the Supervisory Board for the fiscal year 2022
- Appointment of the auditors and group auditors for fiscal year 2022/2023
- Election of a new Supervisory Board member
- Amendments to the Articles of Association relating to the holding of a virtual Annual General Meeting, the virtual participation of Supervisory Board members and the quorum of the Supervisory Board
- Authorization to grant subscription rights (Heidelberg Pharma Stock Option Plan 2023), reduction of individual Conditional Capitals, creation of a Conditional Capital 2023/I, and corresponding amendments to the Articles of Association
- Approval of the remuneration report
Attendance (incl. postal votes cast) at the Annual General Meeting 2023 corresponded to 84,24 % of the current capital stock.
For more information on the Annual General Meeting, including the voting results, please visit: https://heidelberg-pharma.com/en/agm